CompletedNCT04898270
Flupentixol with antipsychotic medicines and metabolic health in schizophrenia
About this title
Read the official source —This study evaluated the effectiveness of Flupentixol for people with schizophrenia.
Medication studyAges 20–65Taiwan
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Flupentixol for people with schizophrenia.
Who was this study for?
Listed age limits: 20 years to 65 years.
- Listed locations
- TaichungSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 19, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Taichung Veterans General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Taiwan
- Age range
- From 20 Years to 65 Years
- Official registry ID
- NCT04898270
- Official title
Show the full official title
Clinical Efficacy and Benefit of Reducing Metabolic Syndrome by Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics (MARTAs) Treated Schizophrenia Patients
Get this study by email
Recruitment & locations
CompletedTaichung
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Flupentixol for people with schizophrenia.
Who is behind this study?
The study sponsor is Taichung Veterans General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Flupentixol and Multi-acting receptor-targeted antipsychotics (MARTAs).
Who was this study for?
Listed age limits: 20 years to 65 years.
